484 related articles for article (PubMed ID: 30099051)
21. Concerted conformational changes control metabotropic glutamate receptor activity.
Lecat-Guillet N; Quast RB; Liu H; Bourrier E; Møller TC; Rovira X; Soldevila S; Lamarque L; Trinquet E; Liu J; Pin JP; Rondard P; Margeat E
Sci Adv; 2023 Jun; 9(22):eadf1378. PubMed ID: 37267369
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
Neuropharmacology; 2016 Dec; 111():253-265. PubMed ID: 27590915
[TBL] [Abstract][Full Text] [Related]
23. Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs.
Flor PJ; Acher FC
Biochem Pharmacol; 2012 Aug; 84(4):414-24. PubMed ID: 22554564
[TBL] [Abstract][Full Text] [Related]
24. Metabotropic glutamate receptor orthosteric ligands and their binding sites.
Acher FC; Cabayé A; Eshak F; Goupil-Lamy A; Pin JP
Neuropharmacology; 2022 Feb; 204():108886. PubMed ID: 34813860
[TBL] [Abstract][Full Text] [Related]
25. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
Lesage A; Steckler T
Eur J Pharmacol; 2010 Aug; 639(1-3):2-16. PubMed ID: 20371230
[TBL] [Abstract][Full Text] [Related]
26. Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators.
Lundström L; Bissantz C; Beck J; Wettstein JG; Woltering TJ; Wichmann J; Gatti S
Br J Pharmacol; 2011 Sep; 164(2b):521-37. PubMed ID: 21470207
[TBL] [Abstract][Full Text] [Related]
27. Allosteric Molecular Switches in Metabotropic Glutamate Receptors.
Orgován Z; Ferenczy GG; Keserű GM
ChemMedChem; 2021 Jan; 16(1):81-93. PubMed ID: 32686363
[TBL] [Abstract][Full Text] [Related]
28. Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators.
Sheffler DJ; Pinkerton AB; Dahl R; Markou A; Cosford ND
ACS Chem Neurosci; 2011 Aug; 2(8):382-93. PubMed ID: 22860167
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
Sanger H; Hanna L; Colvin EM; Grubisha O; Ursu D; Heinz BA; Findlay JD; Vivier RG; Sher E; Lodge D; Monn JA; Broad LM
Neuropharmacology; 2013 Mar; 66():264-73. PubMed ID: 22659090
[TBL] [Abstract][Full Text] [Related]
30. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators.
Rodriguez AL; Nong Y; Sekaran NK; Alagille D; Tamagnan GD; Conn PJ
Mol Pharmacol; 2005 Dec; 68(6):1793-802. PubMed ID: 16155210
[TBL] [Abstract][Full Text] [Related]
31. Conformational fingerprinting of allosteric modulators in metabotropic glutamate receptor 2.
Liauw BW; Foroutan A; Schamber MR; Lu W; Samareh Afsari H; Vafabakhsh R
Elife; 2022 Jul; 11():. PubMed ID: 35775730
[TBL] [Abstract][Full Text] [Related]
32. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
Galici R; Echemendia NG; Rodriguez AL; Conn PJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
[TBL] [Abstract][Full Text] [Related]
33. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
Lindsley CW; Hopkins CR
Expert Opin Ther Pat; 2012 May; 22(5):461-81. PubMed ID: 22506633
[TBL] [Abstract][Full Text] [Related]
34. Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.
Luessen DJ; Conn PJ
Pharmacol Rev; 2022 Jul; 74(3):630-661. PubMed ID: 35710132
[TBL] [Abstract][Full Text] [Related]
35. Molecular Switches of Allosteric Modulation of the Metabotropic Glutamate 2 Receptor.
Pérez-Benito L; Doornbos MLJ; Cordomí A; Peeters L; Lavreysen H; Pardo L; Tresadern G
Structure; 2017 Jul; 25(7):1153-1162.e4. PubMed ID: 28648611
[TBL] [Abstract][Full Text] [Related]
36. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors.
Bräuner-Osborne H; Wellendorph P; Jensen AA
Curr Drug Targets; 2007 Jan; 8(1):169-84. PubMed ID: 17266540
[TBL] [Abstract][Full Text] [Related]
37. Orthosteric and allosteric drug binding sites in the Caenorhabditis elegans mgl-2 metabotropic glutamate receptor.
Tharmalingam S; Burns AR; Roy PJ; Hampson DR
Neuropharmacology; 2012 Sep; 63(4):667-74. PubMed ID: 22652059
[TBL] [Abstract][Full Text] [Related]
38. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.
O'Brien JA; Lemaire W; Chen TB; Chang RS; Jacobson MA; Ha SN; Lindsley CW; Schaffhauser HJ; Sur C; Pettibone DJ; Conn PJ; Williams DL
Mol Pharmacol; 2003 Sep; 64(3):731-40. PubMed ID: 12920211
[TBL] [Abstract][Full Text] [Related]
39. Allosteric modulation of metabotropic glutamate receptors in alcohol use disorder: Insights from preclinical investigations.
Johnson KA; Lovinger DM
Adv Pharmacol; 2020; 88():193-232. PubMed ID: 32416868
[TBL] [Abstract][Full Text] [Related]
40. Functional selectivity induced by mGlu₄ receptor positive allosteric modulation and concomitant activation of Gq coupled receptors.
Yin S; Zamorano R; Conn PJ; Niswender CM
Neuropharmacology; 2013 Mar; 66():122-32. PubMed ID: 22426233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
